Christopher Roche

https://www.sec.gov/Archives/edgar/data/748790/000095012404002498/v99255exv99.htm

MEDICAL DISCOVERIES INC. ANNOUNCES RECEIPT OFCYSTIC FIBROSIS PRE-CLINICAL REPORT ON MDI-PContinuing Pre-IND Research Documents MDI-P Low Toxicity Profile

TWIN FALLS, IDAHO, May 20, 2004 — Medical Discoveries, Inc. (OTC-BB as MLSC) announced the receipt of its third in a series of pre-clinical research reports from Dr. Emil Chi, Chairman of the Department of Histopathology at the University of Washington Medical School. This trial, one of several studies on models of disease which mimic human disease, focused on the company’s proprietary drug MDI-P as a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis (“CF”).

Results from this study showed that, 48 hours after treatment, MDI-P-treated CF-like mice lungs evidenced: a) a 60% reduction in mucus secretion; b) a 49% reduction in white blood cellular infiltration; and c) a 42% reduction in lung edema, as contrasted with untreated CF-like mice. In MDI-P-treated mice, the associated level of lung hemorrhage was reduced by 39%, the level of neutrophil lung infiltration was reduced by 49%, and eosinophil lung infiltration was reduced by 86%, as contrasted with untreated CF-like mice. The 100% MDI-P solution provided a 100% host-sparing effect against this fatal CF-like condition. No overt signs of toxicity were found in the primary organs (lungs, liver, spleen, kidneys, brain) of mice treated with MDI-P. HIV/AIDS RESEARCH FROM THE DANA-FARBER CANCER INSTITUTE MDI has completed a series of validation testing at the Dana-Farber Cancer Institute, a Harvard Medical School teaching Affiliate and National Institute of Health (NIH) approved HIV/AIDS Testing Laboratory. These tests confirmed and extended previous research and testing which demonstrated that MDI-P is shown to be capable of killing HIV cell cultures without mortality to the cells. ADDITIONALLY:

Click link and scroll to description.

https://pubchem.ncbi.nlm.nih.gov/compound/3_4-Methylenedioxy-N-isopropylamphetamine

After being told, she was not a candidate for treatment and she could have 2 to 6 years to live with medication, a nurse stepped in and saved Cindy’s life.